Last reviewed · How we verify
NCT02490813: TCMFA
Pilot Study on Traditional Chinese Medicine and Food Allergy
NA trial testing Treatment - Chinese Herbal Formula - X in Allergy to Fish in 18 participants. Terminated before completion.
18 February 2023
Quick facts
| Lead sponsor | Hong Kong Sanatorium & Hospital |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 18 June 2015 |
| Primary completion | 18 February 2023 |
| Estimated completion | 18 February 2023 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- Treatment - Chinese Herbal Formula - X
- Placebo
Conditions studied
- Allergy to Fish — all drugs for Allergy to Fish →
- Allergy to Shrimp — all drugs for Allergy to Shrimp →
- Allergy to Crab — all drugs for Allergy to Crab →
Sponsor
Hong Kong Sanatorium & Hospital — full company profile →
Who can join
8 and older, any sex, with Allergy to Fish or Allergy to Shrimp. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Recently, there has been an increasing interest in using traditional Chinese medicine for food allergy. The Harvard group has successfully demonstrated the Food Allergy Herbal Formula - FAHF2 completely blocked peanut-induced anaphylaxis in a murine model, and currently being studied in human. Therefore, in collaboration with the Institute of Chinese Medicine, CUHK, the investigators have developed a more simplified Chinese herbal formula - X (CHFX), containing four food-grade Chinese herbs, Wu-mei (Fructus Pruni Mume); Ling-zhi (Gonoderma); Huang-bai (Cortex Phellodendron) and Zhi-su (Perilla frutescens). In the present study, the investigators would like to examine whether there is reduction in allergic symptoms in food challenge after administering the CHFX for 8 weeks. There will be pre- and post- CHFX food challenges and other related tests.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advances in Shellfish Allergy Therapy: From Current Approaches to Future Strategies.
Heidari S, Ruethers T, Karnaneedi S, Yin LWS, et al · · 2025 · cited 4× · PMID 40668267 · DOI 10.1007/s12016-025-09077-8
Verify or expand the search:
- PubMed search for NCT02490813
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Hong Kong Sanatorium & Hospital trials
Trials by the same sponsor.
- NCT07130682 — Two-fraction Proton Therapy With MRI Guidance for Prostate Cancer: A Phase II Trial · NA · recruiting
- NCT05373459 — Effect of a Third COVID-19 Booster Among Health Care Workers · completed
- NCT04898946 — Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong · completed
- NCT04496141 — Evaluation of Commercial SARS-CoV-2 Antibody Immunoassays for COVID-19 · completed
- NCT04416061 — The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02490813 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hong Kong Sanatorium & Hospital
- Last refreshed: 1 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02490813.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing